3.36

1.51% +0.05

After Hours: 3.36

MAIA Biotechnology Inc (MAIA)

Overview News Price History Discussions Forecast

MAIA Biotechnology Inc stock is currently priced at $3.36, with a 24-hour trading volume of 143.77K. It has seen a +1.51% increased in the last 24 hours and a +42.98% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.32 pivot point. If it approaches the $3.41 resistance level, significant changes may occur.

Previous Close:

$3.31

Open:

$3.36

24h Volume:

143.77K

Market Cap:

$68.12M

Revenue:

Net Income/Loss:

$-19.77M

P/E Ratio:

-2.1401

EPS:

-1.57

Net Cash Flow:

$-13.07M

1W Performance:

+14.68%

1M Performance:

+42.98%

6M Performance:

+49.33%

1Y Performance:

+0.00%

1D Range:

$3.24

$3.40

52W Range:

$0.82

$3.59

MAIA Biotechnology Inc Stock (MAIA) Company Profile

Name

MAIA Biotechnology Inc

Sector

Healthcare (1216)

Industry

Biotechnology (700)

Phone

312 416 8592

Address

444 West Lake Street, Suite 1700, Chicago

Employee

Twitter

Next Earnings Date

Latest SEC Filings

MAIA's Discussions on Twitter

MAIA Biotechnology Inc Stock (MAIA) Latest News

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

GlobeNewswire Inc.

MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

GlobeNewswire Inc.

MAIA Soars 20% on Interim Results From Lung Cancer Study

Zacks Investment Research

Why Wipro Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Why VCI Global Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket

Benzinga

Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now

Zacks Investment Research

MAIA Biotechnology Inc Stock (MAIA) Financials Data

MAIA Biotechnology Inc (MAIA) Net Income 2024

MAIA net income (TTM) was -$19.77 million for the quarter ending December 31, 2023, a -25.39% decrease year-over-year.

MAIA Biotechnology Inc (MAIA) Cash Flow 2024

MAIA recorded a free cash flow (TTM) of -$13.07 million for the quarter ending December 31, 2023, a -8.06% decrease year-over-year.

MAIA Biotechnology Inc (MAIA) Earnings per Share 2024

MAIA earnings per share (TTM) was -$1.50 for the quarter ending December 31, 2023, a +1.76% growth year-over-year.

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.